Article

Validity of self-reported pneumococcal vaccination status in the elderly in Spain

Department of Preventive Medicine and Epidemiology, Hospital Clínic, Barcelona, Spain.
Vaccine (Impact Factor: 3.49). 06/2009; 27(34):4560-4. DOI: 10.1016/j.vaccine.2009.05.057
Source: PubMed

ABSTRACT The objective of this study was to evaluate the validity of information reported by the elderly on 23-valent pneumococcal polysaccharide vaccine (23vPPV) vaccination status. A cross-sectional, observational study was carried out in patients aged >or=65 years admitted to five Spanish hospitals. Data on 23vPPV vaccination history were obtained through interview of the patient or close relative and review of written medical information. The validity of the patient self-report was compared to the written medical information by calculation of the sensitivity, specificity, concordance, positive predictive value (PPV) and negative predictive value (NPV). A total of 2484 patients were initially included of whom 1814 patients (73%) responded about their vaccination status. The global sensitivity of the patient self-report was 0.74 and the specificity 0.95. The PPV was 0.92, the NPV 0.84 and the concordance 87. Vaccination cards and centralized vaccination registries in primary health care centres and hospitals should be potentiated in order to ensure that neither more nor less vaccinations are administered than are necessary.

0 Followers
 · 
169 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since 1997, the Advisory Committee on Immunization Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelderly adults with certain medical conditions. In 2008, the Committee added asthma and cigarette smoking to the list of indications for PPSV23 vaccination. Using data from the 2009 National Health Interview Survey, the authors assessed PPSV23 uptake in people with established and new indications. To identify factors independently associated with receiving PPSV23, they used multivariable logistic regression and predictive marginal analyses. In 2009, a total of 35.2 million adults 18-64 years of age (18.6%) had established PPSV23 indications; adding asthma and smoking to the list of indications increased the high-risk population to 71.6 million people (37.9%). Overall, 26.1% of people with established indications for PPSV23 and 17.4% of people with any indication (those previously established, as well as asthma and smoking) had received the vaccine; overall coverage among persons 50-64 years of age was significantly higher than that among persons 18-49 years of age (34.6% vs. 16.7%; P < 0.001) and for all specific indications except cancer. For persons who had asthma or who smoked but had no other indications, rates of coverage were 12.3% and 8.5%, respectively. In persons who had established indications, being older, white, and unemployed and having more physician visits, a prior hospitalization, a regular physician, and health insurance were independently associated with PPSV23 receipt. PPSV23 uptake varies substantially by age and indication but remains low overall, with approximately 59 million unvaccinated high-risk working-age adults. Effective strategies to increase pneumococcal vaccination coverage among at-risk groups are needed.
    American journal of epidemiology 03/2012; 175(8):827-37. DOI:10.1093/aje/kwr376 · 4.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Galicia has issued specific recommendations on the use of vaccines in adults, directed at the general populations and specific groups. The aim of this study is to assess Galician population knowledge on vaccination in adults.Methods In 2010, 7,845 Galician adults aged over 15 years completed a telephone survey concerning health risk behaviours and preventive health practices within the context of its periodical surveillance system (SICRI). The sampling unit was the individual and the sample was representative by sex and age groups: 16-24, 25-44, 45-64 and 65 years and over. Data regarding vaccination among adults were obtained from 4 questions, 2 related to general knowledge and 2 about international travel.ResultsOver 70% of the population reported adulthood vaccination as important, and a similar percentage correctly identified recommended vaccines for adults, mainly for flu. As regards travel vaccination, 56% thought that vaccines were sometimes necessary before international travel. Most people did not correctly identify the places where to seek travel health information. Educational level was directly related with vaccine knowledge.Conclusions Large-scale influenza immunisation campaigns have had a profound impact on vaccine knowledge among target groups, such as the elderly population. Information about other vaccines recommended for adults must be improved, taking into account educational differences.
    Vacunas 01/2013; 14(1):11–16. DOI:10.1016/j.vacun.2013.03.001
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: While many countries have robust child immunization programs and high child vaccination coverage, vaccination of adults has received less attention. The objective of this study was to describe the adult vaccination policies in developed countries. METHODS: From 2010 to 2011, we conducted a survey of 33 advanced economies as defined by the International Monetary Fund. The survey asked about national recommendations for adults for 16 vaccines or vaccine components, funding mechanisms for recommended adult vaccines, and the availability of adult vaccination coverage estimates. RESULTS: Thirty-one of 33 (93.9 %) advanced economies responded to the survey. Twelve of 31 (38.7 %) reported having a comprehensive adult immunization schedule. The total number of vaccines or vaccine components recommended for adults ranged from one to 15 with a median of 10. Seasonal influenza (n = 30), tetanus (n = 28), pneumococcal polysaccharide (n = 27), and hepatitis B (n = 27) were the most frequently recommended vaccines or components. CONCLUSIONS: Approximately two-thirds of survey respondents do not have a comprehensive adult vaccine schedule, and most do not measure vaccination coverage. We found that a funding mechanism is available for most recommended adult vaccines.
    International Journal of Public Health 01/2013; 58(6). DOI:10.1007/s00038-012-0438-x · 2.70 Impact Factor
Show more